Evidence map›Paper›PMID 34035312›Full record

Trial reportNPJ primary care respiratory medicine2021

Single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy versus tiotropium monotherapy in patients with COPD.

Sandeep Bansal, Martin Anderson, Antonio Anzueto, Nicola Brown, Chris Compton, Thomas C Corbridge, David Erb, Catherine Harvey, Morrys C Kaisermann, Mitchell Kaye and 4 more

2 registry-linked trialsOpen access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in NPJ primary care respiratory medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 9 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 5 pooled it
5.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03474081 phase4completednot on this map

A Phase IV, 12 Week, Randomised, Double-blind, Double-dummy Study to Compare Single Inhaler Triple Therapy, Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI), With Tiotropium Monotherapy Based on Lung Function and Symptoms in Participants With Chronic Obstructive Pulmonary Disease

TypeinterventionalSponsorGlaxoSmithKlineRan2018 to 2019Enrolled800ConditionsPulmonary Disease, Chronic ObstructiveArmsFF/UMEC/VI, Tiotropium, Albuterol/salbutamol, Placebo to match FF/UMEC/VI, Placebo to match tiotropium
NCT06905483 phase4completednot on this mapstarted 2025, after this paper: background citation

Comparative Effects of Triple Inhaled Therapy With Budesonide/Glycopyrronium/Formoterol Versus Fluticasone Furoate/Umeclidinium/Vilanterol on Small Airway Disease in COPD Patients: A Randomized Crossover Study

TypeinterventionalSponsorThammasat UniversityRan2025 to 2026Enrolled22ConditionsCOPD, Chronic Obstructive Pulmonary Disease (COPD), Small Airway Disease, Triple TherapyArmsBudesonide/Glycopyrronium/Formoterol (BGF), Fluticasone Furoate/Umeclidinium/Vilanterol (FUV)
3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 5 syntheses or guidelines pooled it, 40 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Article
  7. Observational
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 7 institutions in 4 countries.

Sandeep BansalThe Lung Center, Penn Highlands Healthcare, Du Bois, PA, USA.
Martin AndersonKarolinska Institutet, Stockholm, Sweden.
Antonio AnzuetoDivision of Pulmonary Diseases and Critical Care Medicine, School of Medicine, The University of Texas Health Science Center, San Antonio, TX, USA.
Nicola BrownGSK, Stockley Park West, Iron Bridge Road North, West Drayton, Uxbridge, Middlesex, UK.
Chris ComptonGSK, Brentford, Middlesex, UK.
Thomas C CorbridgeGSK, Research Triangle Park, NC, USA.
David ErbVitaLink Research Gaffney, Gaffney, SC, USA.
Catherine HarveyGSK, Stockley Park West, Iron Bridge Road North, West Drayton, Uxbridge, Middlesex, UK.
Morrys C KaisermannGSK, Collegeville, PA, USA.
Mitchell KayeMinnesota Lung Center, Minneapolis, MN, USA.
David A LipsonGSK, Collegeville, PA, USA.ORCID 0000-0001-6732-4593
Neil MartinGSK, Brentford, Middlesex, UK.
Chang-Qing ZhuGSK, Stockley Park West, Iron Bridge Road North, West Drayton, Uxbridge, Middlesex, UK.
Alberto PapiRespiratory Unit, Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Ferrara, FE, Italy. ppa@unife.it.ORCID 0000-0002-6924-4500
GlaxoSmithKline (United States) · USKarolinska Institutet · SENorthwestern University · USPenn Highlands Healthcare · USThe University of Texas Health Science Center at San Antonio · USUniversity of Ferrara · ITUniversity of Leicester · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic obstructive pulmonary disease (COPD) treatment guidelines do not currently include recommendations for escalation directly from monotherapy to triple therapy. This 12-week, double-blind, double-dummy study randomized 800 symptomatic moderate-to-very-severe COPD patients receiving tiotropium (TIO) for ≥3 months to once-daily fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) 100/62.5/25 mcg via ELLIPTA (n = 400) or TIO 18 mcg via HandiHaler (n = 400) plus matched placebo. Study endpoints included change from baseline in trough forced expiratory volume in 1 s (FEV

Indexed as

Bronchodilator AgentsPulmonary Disease, Chronic ObstructiveAdministration, InhalationAndrostadienesBenzyl AlcoholsChlorobenzenesDouble-Blind MethodForced Expiratory VolumeHumansNebulizers and VaporizersQuinuclidinesTiotropium BromideTreatment OutcomeAndrostadienesBenzyl AlcoholsBronchodilator AgentsChlorobenzenesfluticasone furoateGSK573719QuinuclidinesTiotropium Bromidevilanterol

Identifiers

PMID34035312
PMCPMC8149706
OpenAlexW3164397367

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.